Mukka Proteins delays Vietnam acquisition to Dec 2026
Mukka Proteins Ltd has delayed its acquisition of a 70% stake in Mukka Proteins Vietnam Co., Ltd. to 31 December 2026 due to pending regulatory approvals. The transaction, valued at up to ₹10,00,000, was initially slated for completion by 30 June 2026.

*this image is generated using AI for illustrative purposes only.
Mukka Proteins Ltd has announced a delay in its acquisition of Mukka Proteins Vietnam Co., Ltd., pushing the revised completion date to 31 December 2026. The company attributed the postponement to delays in securing necessary regulatory approvals in Vietnam. This development impacts the proposed purchase of a 70% stake in the target entity through share transfer.
The acquisition was initially expected to be completed by 30 June 2026. The company had previously submitted intimations regarding this transaction on 26 July 2025, 4 August 2025, and 31 December 2025 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The total consideration for the acquisition does not exceed ₹10,00,000. Mukka Proteins stated that all necessary steps are being taken to address the delays and complete the acquisition in due course.
Acquisition Details
| Details of the acquisition | |
|---|---|
| Name of the Acquiring Company | Mukka Proteins Limited |
| Name of the Target Company | Mukka Proteins Vietnam Co., Ltd. |
| Announcement Date | 26th July 2025 and 31st December 2025 |
| Expected Date of Completion of Acquisition | 30th June 2026 |
| Revised Date of Completion | 31st December 2026 |
| Reason for Delay | Delay in getting the regulatory approvals in Vietnam |
Historical Stock Returns for Mukka Proteins
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.07% | -3.31% | +6.16% | +1.54% | -22.86% | -45.37% |
What specific regulatory hurdles in Vietnam are causing the delay, and are they industry-specific?
How will this extended timeline impact Mukka Proteins' strategic expansion plans in Southeast Asia?
Could further delays be anticipated, and what contingency plans are in place if approvals are not secured by December 2026?































